CoDa Therapeutics Lands $20M More

San Diego-based CoDa Therapeutics, which develops biopharmaceuticals aimed at wound care, said today that it has added $20M to its Series B financing round. The new funding, a second close, came from RusnanoMedInvest. CoDa Therapeutics said the new funding brings its Series B to nearly $40M. Domain Associates, GBS Ventures, and BioPacificVentures also participated in the round. CoDa said the investment from RUSNANO came as part of a joint investment agreement between RUSNANO and Domain Associates, which those two firms entered in March of 2012. CoDa Therapeutics said the new funds will go to expand late stage clinical trials for its lead product candidate, being targeted at treating diabetic foot ulcers. More information »